Form 4: Guardant Health CMO's RSU Vesting & Tax Withholding

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and a corresponding disposition of shares for tax obligations.

Summary

• Craig Eagle, Chief Medical Officer of Guardant Health, Inc. (GH), reported changes in beneficial ownership.
• On October 1, 2025, multiple tranches of Restricted Stock Units (RSUs) vested, resulting in the acquisition of common stock.
• A total of 1,714 shares, 1,668 shares, and 10,477 shares of common stock were acquired through RSU vesting.
• Concurrently, 7,025 shares were disposed of at a price of $62.65 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Craig Eagle directly beneficially owns 44,316 shares of common stock.
• Remaining unvested derivative securities include 6,857, 6,669, and 21,274 Restricted Stock Units from awards granted in November 2022, December 2023, and November 2024, respectively.

Sentiment

Score: 6

Explanation: The filing reflects routine executive compensation activities, specifically the vesting of RSUs and subsequent tax-related share dispositions. This is a neutral event, but the continued vesting and retention of a significant number of shares by a key officer can be seen as a minor positive for management alignment.

Positives

• The vesting of Restricted Stock Units indicates continued compensation and alignment of management interests with shareholders.
• The disposition of shares was solely for tax withholding, a standard practice, rather than a discretionary sale by the officer.

Negatives

• A portion of the vested shares (7,025 shares) was sold to cover tax liabilities, reducing the officer's direct beneficial ownership from the gross vested amount.

Risks

• No specific risks related to the company's operations or financial health were disclosed in this Form 4 filing.

Future Outlook

Future vesting events for Craig Eagle's remaining Restricted Stock Units are scheduled to occur in equal quarterly installments over the next two to three years, based on the original grant terms.

Industry Context

This filing is a routine insider transaction report related to executive compensation and does not provide broader insights into industry trends or competitive landscape for Guardant Health, which operates in the precision oncology and diagnostics sector.

Stakeholder Impact

• Shareholders: Minor, routine impact as it reflects standard executive compensation practices and does not indicate a change in company strategy or financial performance.
• Employees: No direct impact mentioned.

Next Steps

• Continued quarterly vesting of remaining Restricted Stock Units from the November 7, 2022 award over the next three years.
• Continued quarterly vesting of remaining Restricted Stock Units from the December 13, 2023 award over the next two years.
• Continued quarterly vesting of remaining Restricted Stock Units from the November 8, 2024 award over the next two years.

Key Dates

Keywords

Guardant Health, GH, Craig Eagle, Chief Medical Officer, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Compensation, Tax Withholding